



## Global Kinetics Corporation and the PKG™

GKC is on a trajectory to revolutionize the management of Parkinson's disease by enabling informed treatment decisions which are based on continuous and objective measurement of patients' key movement symptoms in everyday environments.

Our PKG technology:

- Technically de-risked and established in market – over **3,000,000 hours of continuous Parkinson's monitoring delivered to date, representing more than 25,000 patient PKGs**
- Changes clinical decisions more than 50% of the time
- Boasts significant key opinion leader support
- Is underpinned by robust clinical validation and regulatory clearance through FDA 510(k) in the USA, CE mark in Europe, TGA Class IIA ARTG 236583 listed

For every diabetic patient, at every appointment, every doctor requires an accurate and current blood glucose assessment to support their clinical decisions. Our vision is that for every Parkinson's patient, every doctor will require a PKG.

**Global Kinetics Corporation – proudly partnering for treatment of Parkinson's.**

### Global Kinetics Corporation:

Global Kinetics Corporation (GKC) was established in 2007 to commercialise innovative technology developed by Professor Malcolm Horne, from the Florey Institute of Neuroscience & Mental Health (the largest Neuroscience research team in Australia and the Southern Hemisphere), and Dr Rob Griffiths, for the precise recording, quantification and reporting of movement symptoms of neurological disease.

Headquartered in Melbourne, Australia, with offices in Minneapolis, USA and London, UK, GKC is a privately-held commercial-stage digital health company revolutionising the management of Parkinson's disease by providing the first continuous and objective measurement of patients' symptoms in everyday environments.

The company's PKG™ system creates data-driven reports that enhance clinical decision making and enable more personalised treatment.

### Directors

Mr John E. Schellhorn

Dr. J. Leighton Read, BSc, MD

Prof. Malcolm K. Horne, BMedSci (Hons), PhD, MBBS (Hons), FRACP

Dr. Thomas Lönngren  
PhD h.c. MRPharmS, FRCP

Dr. Christopher D. Nave,  
BSc (Hons), PhD

### Executive team

President and CEO:  
Mr John E. Schellhorn

Chief Scientific Officer (Co-Founder):  
Prof. Malcolm K. Horne, BMedSci (Hons), PhD, MBBS (Hons), FRACP

Chief Financial Officer:  
Thomas G. Howitt, BCom, ACA, AICPA, ACS, TIA

Vice President, Clinical Affairs and Reimbursement:  
Peter M. Lynch, MPH

Senior Vice President, Business Development and Legal Affairs:  
Michelle A. Goldsmith, LLB (Hons), BSc

Vice President, Product Development:  
Brendan Fafiani BSc (Hons)


Chief Commercialization Officer  
John Bojanowski

Chief Operating Officer and GM China  
Brooke Ren PhD

## Parkinson's pathology market


Parkinson's disease (PD) is a fluctuating disorder that has relied on subjective, point in time observation and assessment to guide therapeutic decisions. Effective treatments exist for PD; however, selecting and titrating those treatments is difficult given the limited information gained from subjective, patient-reported symptomology. It is estimated that up to 80% of PD patients are uncontrolled. Uncontrolled patients have lower Quality of Life and cost the health care system twice as much as that of controlled patients. This problem can be improved with the use of the Personal KinetiGraph™ (PKG™), an innovative mobile health technology, developed by Global Kinetics.

**The PKG is the World's only FDA cleared continuous, objective, ambulatory assessment of the treatable disabling symptoms of Parkinson's. This leads to more informed treatment decisions, potentially better quality of life and reduced costs.**



## Corporate overview

Name	Global Kinetics Corporation Limited (GKC)
Status	Privately-held Australian company
Locations	Australia (headquarters), USA and UK
Personnel	42 FTE (Australia 19; USA 7; Europe Union 12)
Financings	Five private rounds, all at progressively higher prices
Industry/sector	Neurology - Parkinson's disease and other movement disorders



## Pathways to Recurrent Funding

In 2014 GKC entered selected Northern European markets to develop evidence, education, advocacy and marketing strategies. GKC has successfully secured recurrent funding in several European countries. With long term growth and high volumes in mind, GKC is using this platform to demonstrate the clinical and health economic value of the PKG in order to accelerate reimbursement in the US and other countries.

## Partnership Offering

GKC partners with leading international healthcare and technology companies to:

- reduce the time and cost of clinical studies
- identify patients for their therapies through screening protocols
- optimise and personalise therapy; and
- introduce new methods of service delivery



PKG™ is Personal KinetiGraph in the USA and Parkinson's KinetiGraph™ in the rest of the world. PKG™ and KinetiGraph™ are trademarks of Global Kinetics Corporation Ltd.

Global Kinetics Corporation Ltd.  
Level 9/31 Queen Street Melbourne Victoria, Australia 3000.  
info@globalkineticscorp.com | www.globalkineticscorp.com

**References:** 1. Dorsey et. al (2007) "Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030." Neurology 2007; 68: 384-386.  
GKC-8000-EN105-V1-GKC Media Sheet 9 April 2018

